Morgan Lewis today welcomes back David C. Schwartz, a lawyer who focuses on capital markets and corporate finance transactions, mergers and acquisitions, and securities law matters primarily in the life sciences, healthcare, and technology industries. He is resident in the firm’s Princeton office. Before rejoining Morgan Lewis, David was as a partner at another global law firm, resident in Short Hills, NJ.
David advises a broad range of clients, including startups and emerging companies, publicly held middle-market companies, venture capital firms, and underwriters. His experience includes initial public offerings (IPOs), private investments in public equity (PIPEs), confidentially marketed public offerings, and direct follow-on offerings, as well as venture capital, private equity, mergers and acquisitions, and going-private and other strategic transactions.
“We know David well and we are delighted to welcome him back to Morgan Lewis,” said Firm Chair Jami McKeon. “Our clients in the life sciences industry, especially those involved in biotechnology, will benefit from his deep experience, and we are excited about the synergies his corporate practice will bring to our thriving FDA, intellectual property, and labor and employment practices.”
David regularly serves as counsel for private and public companies at various stages of development and provides general corporate representation, including advice to boards of directors and management concerning corporate governance matters.
“David’s strong transactional, securities compliance, and capital markets background will further strengthen our capital markets and public companies practice,” said Steve Browne, leader of Morgan Lewis’s global corporate and business transactions practice. “His extensive experience, coupled with his deep industry knowledge, will be invaluable to our startup and emerging-growth clients in the life sciences and biotechnology industries in particular.”
David’s arrival follows that of two corporate of counsel who recently joined the firm resident in Princeton: Al Bristow, who focuses on life sciences transactions and emerging growth businesses, and Veronica DiCamillo, who concentrates on public and private company mergers and acquisitions, private equity investments, and corporate governance matters.